Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Digoxin × Head & Neck × Clear all

Phase

Phase NA 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2 Other hematologic neoplasm 1 Myeloid 1 Head & Neck 1

Conditions

Head and Neck Neoplasms 1

Interventions

pembrolizumab 58 Cisplatin 35 Cetuximab 29 Nivolumab 24 Radiotherapy 23 Paclitaxel 19 Carboplatin 19 Docetaxel 16 durvalumab 11 Radiotherapy, Intensity-Modulated 10 Gemcitabine 8 Fluorouracil 8 Cyclophosphamide 8 tremelimumab 7 Ipilimumab 7 toripalimab 6 epacadostat 6 Erlotinib Hydrochloride 6 spartalizumab 5 fludarabine 5 avelumab 5 Interleukin-2 5 Bevacizumab 5 tislelizumab 4 cemiplimab 4 aldesleukin 4 Pemetrexed 4 Immune Checkpoint Inhibitors 4 Gefitinib 4 Everolimus 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02906800 2017-10-19

DIGHANC

Assistance Publique - Hôpitaux de Paris

Phase 1/2 Unknown

Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡